Novo Nordisk A/S
NVO
Positions held
Your positionsNVO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Novo Nordisk operates in a competitive landscape with a strong focus on diabetes and obesity treatments, positioning itself as a leader in the healthcare sector.
- The company reported a revenue of $78.5 billion in Q2 2026, although this reflects a 19% decrease from the previous quarter.
- Despite the revenue drop, Novo Nordisk maintains a solid gross margin of 78.2%.
- The healthcare industry is facing regulatory pressures that could impact drug pricing and reimbursement policies, which may affect Novo Nordisk's profitability.
- Novo Nordisk's earnings growth is currently at -20.6%, indicating potential challenges in maintaining profitability.
- The company's stock has a 'Strong Sell' signal with a score of -24.00, reflecting negative market sentiment.
Fundamentals
| Market cap | $168.54B | Enterprise value | $264.21B | Trailing P/E | 9.33 | Forward P/E | 11.53 |
| PEG | 4.43 | Price / book | 5.04 | Beta | 0.38 | Dividend yield | 4.71% |
| Revenue growth | 2.1% | Earnings growth | -20.6% | Gross margin | 82.0% | Operating margin | 42.5% |
| Profit margin | 35.3% | ROE | 59.8% | ROA | 18.7% | Debt / equity | 0.63 |
| Current ratio | 0.87 | Free cash flow | $37.67B | Analyst recommendation | hold | Mean target | $46.14 |
| 52w high | $64.16 | 52w low | $35.12 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $78.5B | $96.8B | $79.1B | $75.0B | $76.9B | — |
| Op margin | 34.5% | 61.6% | 40.1% | 31.6% | 43.5% | — |
| Net income | $21.0B | $48.6B | $26.9B | $20.0B | $26.5B | — |
| Gross margin | 78.2% | 86.0% | 80.9% | 76.1% | 83.3% | — |
| Gross profit | $61.4B | $83.2B | $64.0B | $57.1B | $64.0B | — |
| Operating income | $27.1B | $59.6B | $31.7B | $23.7B | $33.4B | — |
- Revenue -19% vs prior quarter ($78.5B vs $96.8B).
- Gross margin 78.2% (was 86% prior quarter).
- Operating margin compressed to 34.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $309.1B | $290.4B | $232.3B | $177.0B |
| Op margin | 41.3% | 44.2% | 44.2% | 42.3% |
| Net income | $102.4B | $101.0B | $83.7B | $55.5B |
| Gross margin | 81.0% | 84.7% | 84.6% | 83.9% |
| Gross profit | $250.3B | $245.9B | $196.5B | $148.5B |
| Operating income | $127.7B | $128.3B | $102.6B | $74.8B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data Land
2026-10-09 · Novo Nordisk stock target cut at Citi on lack of margin growth
2026-10-09 · UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
2026-10-08 · LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
2026-10-08 · Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response
2026-10-07 · Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
2026-10-07 · Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.
2026-10-07 · VKTX Advances Obesity Program With New Oral Maintenance Study
2026-10-07 · European Equities Traded in US as ADRs Fall in Wednesday Trading
2026-10-07 · Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
Price (daily)
Full chart · RSI · MACD · patterns